- Report
- August 2022
- 120 Pages
Global
From €4539EUR$4,750USD£3,862GBP
- Report
- August 2021
- 120 Pages
Global
From €4253EUR$4,450USD£3,618GBP
- Report
- March 2019
- 108 Pages
Global
From €4109EUR$4,300USD£3,496GBP
- Report
- July 2018
- 37 Pages
Global
From €9556EUR$10,000USD£8,131GBP
- Report
- July 2018
- 33 Pages
Global
From €9556EUR$10,000USD£8,131GBP
- Report
- July 2018
- 16 Pages
Global
From €9556EUR$10,000USD£8,131GBP
- Drug Pipelines
- February 2018
- 35 Pages
Global
From €9556EUR$10,000USD£8,131GBP
- Drug Pipelines
- February 2018
- 35 Pages
Global
From €9556EUR$10,000USD£8,131GBP
- Report
- May 2022
- 156 Pages
Global
From €3823EUR$4,000USD£3,252GBP
- Report
- June 2021
Global
From €3823EUR$4,000USD£3,252GBP
- Report
- May 2019
- 357 Pages
Global
From €3823EUR$4,000USD£3,252GBP
- Report
- January 2023
- 191 Pages
Global
From €3440EUR$3,600USD£2,927GBP
- Report
- January 2023
- 64 Pages
North America
From €1433EUR$1,500USD£1,220GBP
- Report
- March 2022
- 205 Pages
Global
From €3440EUR$3,600USD£2,927GBP
- Report
- March 2022
- 90 Pages
Middle East, Africa
From €1433EUR$1,500USD£1,220GBP
- Report
- March 2022
- 90 Pages
Asia Pacific
From €1433EUR$1,500USD£1,220GBP
- Report
- March 2022
- 90 Pages
Europe
From €1433EUR$1,500USD£1,220GBP
- Report
- March 2022
- 81 Pages
North America
From €1433EUR$1,500USD£1,220GBP
- Report
- April 2024
- 80 Pages
Argentina
From €2480EUR$2,595USD£2,110GBP
- Report
- April 2024
- 80 Pages
Brazil
From €2480EUR$2,595USD£2,110GBP
The Dry Powder Inhaler (DPI) market is a segment of the respiratory drugs market. It is a device used to deliver medication to the lungs in the form of a dry powder. It is a convenient and efficient way to deliver medication to the lungs, as it does not require the use of a propellant gas. DPIs are used to treat a variety of respiratory conditions, such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. They are also used to deliver vaccines and other medications.
DPIs are becoming increasingly popular due to their convenience and effectiveness. They are also cost-effective, as they require fewer components than other inhalers. Additionally, DPIs are easy to use and can be used by patients of all ages.
Several companies are involved in the DPI market, including GlaxoSmithKline, Boehringer Ingelheim, Novartis, Merck, and AstraZeneca. These companies are involved in the development, manufacture, and marketing of DPIs. Show Less Read more